Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00976027 · ClinicalTrials.gov registry record · Phase 3
Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 9,172
- Enrollment target
NCT00976027 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 9,172 participants.
The verdict
NCT00976027, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 9,172 participants
- Enrollment target
Study Summary
The aim of this study is to determine the efficacy of Fluzone High Dose vaccine and that of Fluzone® vaccine in the elderly. Primary objective: To measure the efficacy of the vaccine, defined as the prevention of laboratory-confirmed influenza caused by viral types/subtypes that are antigenically similar to those contained in the respective annual vaccine formulations. Secondary objectives: * To compare the clinical efficacy of Fluzone High Dose vaccine with that of Fluzone® vaccine in elderly adults, with respect to laboratory-confirmed influenza illness caused by any type or subtype of influenza virus. * To compare the clinical efficacy of Fluzone High Dose vaccine with that of Fluzone® vaccine in elderly adults, in preventing culture-confirmed influenza illness caused by viral types/subtypes antigenically similar to those contained in the respective annual vaccine formulations.
Interventions
- BIOLOGICAL Trivalent inactivated influenza vaccine
- BIOLOGICAL Trivalent inactivated influenza vaccine High Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,172 participants |
| Start Date | 2009-09 |
| Est. Completion | 2012-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00976027
The ClinicalTrials.gov registry entry for NCT00976027 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 9,172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trivalent inactivated influenza vaccine is the first listed.
NCT00976027 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00976027 about?
NCT00976027 is a clinical study titled "Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older". The aim of this study is to determine the efficacy of Fluzone High Dose vaccine and that of Fluzone® vaccine in the elderly. Primary objective: To measure the efficacy of the vaccine, defined as the prevention of laboratory-confirmed influenza caused by viral types/subtypes that are antigenically ...
What is the current status of trial NCT00976027?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 9,172 participants. The study started on 2009-09. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00976027?
The interventions under investigation include: Trivalent inactivated influenza vaccine (BIOLOGICAL), Trivalent inactivated influenza vaccine High Dose (BIOLOGICAL).
Who is sponsoring clinical trial NCT00976027?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.